Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers
靶向ALC1可以安全地扩大PARP抑制剂在高级别浆液性卵巢癌中的治疗应用范围。
期刊:
影响因子:
doi:10.64898/2025.12.04.692458
Aubuchon, Lindsey N; Wong, Deanna H; Ramakrishnan, Natasha M; Reddy, Rohan; Compadre, Amanda; Lomonosova, Elena; Jackson, Kathleen E; Kemper, Danielle; Mehta, Vrutti; Zoberi, Kellen; Khabele, Dineo; Christie, Elizabeth L; Mullen, Mary M; Verma, Priyanka